648934-08-1

Upstream product

• 849796-53-8 (2R)-(N'-benzyloxycarbonylaminooxymethyl)-6-oxa-3-azabicyclo[3.1.0]hexane-3-carboxylic acid tert-butyl ester 
• 74844-93-2 N-BOC-3,4-didehydro-(S)-proline methyl ester 
• 648934-06-9 (2R)-(N'-benzyloxycarbonylaminooxymethyl)-6-oxa-3-azabicyclo[3.1.0]hexane-3-carboxylic acid tert-butyl ester 
• 648934-02-5 (S)-(N'-benzyloxycarbonylaminooxymethyl)-2,5-dihydropyrrole-1-carboxylic acid 1-tert-butyl ester 
• 648934-04-7 (S)-2-methanesulfonyloxymethyl-2,5-dihydropyrrole-1-carboxylic acid tert-butyl ester 
• 205444-34-4 (S)-tert-butyl 2-(hydroxymethyl)-2,5-dihydro-1H-pyrrole-1-carboxylate 
• 51154-06-4 (S)-2,5-dihydropyrrole-1,2-dicarboxylic acid 1-tert-butyl ester 

Relevant academic research and scientific papers

cis-6-oxo-hexahydro-2-oxa-1,4-diazapentalene and cis-6-oxo- hexahydropyrrolo[3,2-c]pyrazole based scaffolds: Design rationale, synthesis and cysteinyl proteinase inhibition

The 5,5-bicycles cis-6-oxo-hexahydro-2-oxa-1,4-diazapentalene 3 and cis-6-oxo-hexahydropyrrolo[3,2-c]pyrazole 4 were designed as rotationally restricted templates towards the preparation of inhibitors of CAC1 cysteinyl proteinases. The design strategy was

BIOLOGICALLY ACTIVE COMPOUNDS

Compounds of general formula (I) wherein: Z = CR3R4, where R3 and R4 are independently chosen from CO-7-alkyl P1 = CR5R6, P2 = O, CR7R8/sup